Bloomberg News

Pharmstandard Falls to 3-Year Low as UralSib Cuts Estimate

June 06, 2012

OAO Pharmstandard (PHST) fell to a three- year low in London after Uralsib Capital cut its price estimate following a decline in first-quarter revenue.

Pharmstandard’s global depositary receipts lost 2.4 percent to $12.80 as of 4:27 p.m. in London, the lowest level since June 2009. The GDRs fell as much as 20 percent to $10.51 earlier.

Uralsib cut its 2012 price estimate 13 percent to $21, according to an e-mailed note. First-quarter revenue fell 31 percent to 2.93 billion rubles ($90 million) from a year earlier, the company said on May 16.

To contact the reporter on this story: Ksenia Galouchko in Moscow at kgalouchko1@bloomberg.net;

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net


Monsanto vs. GMO Haters
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus